Milton Werner - Inhibikase Therapeutics President CEO
| IKT Stock | USD 2.34 0.03 1.30% |
CEO
Milton Werner is President CEO of Inhibikase Therapeutics
| Age | 60 |
| Address | 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 |
| Phone | 678 392 3419 |
| Web | https://www.inhibikase.com |
Milton Werner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Milton Werner against Inhibikase Therapeutics stock is an integral part of due diligence when investing in Inhibikase Therapeutics. Milton Werner insider activity provides valuable insight into whether Inhibikase Therapeutics is net buyers or sellers over its current business cycle. Note, Inhibikase Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Inhibikase Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Milton Werner over six months ago Acquisition by Milton Werner of 45000 shares of Inhibikase TherapeuticsInc at 2.16 subject to Rule 16b-3 | ||
Milton Werner over six months ago Acquisition by Milton Werner of 210000 shares of Inhibikase TherapeuticsInc at 0.74 subject to Rule 16b-3 |
Inhibikase Therapeutics Management Efficiency
The company has Return on Asset of (0.7621) % which means that on every $100 spent on assets, it lost $0.7621. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4969) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2024. Return On Capital Employed is likely to gain to -1.72 in 2024. At this time, Inhibikase Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 85.6 K in 2024.Similar Executives
| Found 11 records | CEO Age | ||
| LLM JD | Tempest Therapeutics | 54 | |
| Mohamed Hashad | Longeveron LLC | 62 | |
| Joseph MBA | Milestone Pharmaceuticals | 56 | |
| Dietrich MBA | DiaMedica Therapeutics | 53 | |
| John Tucker | Scpharmaceuticals | 61 | |
| Shaun Bagai | RenovoRx | 47 | |
| Gareth Sheridan | Nutriband | 34 | |
| Eric MBA | Seres Therapeutics | 48 | |
| Mohamed MBA | Longeveron LLC | 62 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| Dr MBA | Oncolytics Biotech | N/A | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 |
Inhibikase Therapeutics Leadership Team
Elected by the shareholders, the Inhibikase Therapeutics' board of directors comprises two types of representatives: Inhibikase Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inhibikase. The board's role is to monitor Inhibikase Therapeutics' management team and ensure that shareholders' interests are well served. Inhibikase Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inhibikase Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Rush, Head Research | ||
| Milton Werner, President CEO | ||
| BSc FRCPC, Interim Advisor | ||
| Garth LeesRolfe, Chief Officer | ||
| Joseph CPA, Chief Officer | ||
| Surendra Singh, Manufacturing Chemistry | ||
| Dan Williams, Controller | ||
| Garth CPA, Chief Officer |
Inhibikase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inhibikase Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 154.13 M | ||||
| Shares Outstanding | 67.19 M | ||||
| Shares Owned By Insiders | 10.46 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 187.95 K | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 1,976 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.